News

June 3, 2019

BVAS and FFS Both Useful Tools for Predicting AAV Prognosis and Choosing Therapy, Study Says

News

The Birmingham Vasculitis Activity Score (BVAS) and the Five Factors Score (FFS) are both useful tools for predicting the prognosis of ANCA-associated vasculitis, and for selecting the best first-line ... Read more

May 30, 2019May 30, 2019

Rituxan-Soliris Combo May Replace Glucocorticoids in Treatment of Severe AAV, Case Report Suggests

News

A combination of Rituxan (rituximab) and Soliris (eculizumab) may be used to replace glucocorticoids for the treatment of patients with severe ANCA-associated vasculitis, a case report suggests. The report, ... Read more

May 28, 2019May 28, 2019

Blood in Urine Linked to Higher Risk of Kidney Disease Relapse in AAV Patients, Study Finds

News

The presence of blood in the urine is associated with a four times higher risk of kidney disease relapse within 44 months after achieving remission in patients with ANCA-associated ... Read more

May 27, 2019May 24, 2019

Agency Unveils RaDaR to Help Patient Groups Develop Rare Disease Registries

News

RaDaR, the catchy new name for the U.S. government-run Rare Diseases Registry Program, aims to help patient advocacy groups with limited resources build their own disease registries. The site ... Read more

May 23, 2019

Urinary Gremlin Protein Levels a Potential Biomarker for ANCA-associated Renal Vasculitis, Study Finds

News

Levels of Gremlin — a protein that is overexpressed during kidney damage — in the urine may serve as a specific biomarker for ANCA-associated renal vasculitis, a study shows. ... Read more

May 21, 2019

First Patient Dosed in European Trial Testing IFX-1 Investigational Therapy, InflaRx Announces

News

The first patient has been dosed in InflaRx‘s ongoing European Phase 2 clinical trial testing the safety and efficacy of its IFX-1 investigational therapy for the treatment of ANCA-associated ... Read more

May 15, 2019

Rare Diseases Constitute a ‘Public Health Issue,’ NCATS Director Warns

News

With 250 rare diseases newly identified every year, scientists can barely keep up — even as the healthcare system fails millions of Americans whose rare diseases have already been ... Read more

May 14, 2019

ChemoCentryx on Track to Present Topline Data From its Ongoing ADVOCATE Phase 3 Trial on Avacopan

News

ChemoCentryx remains on track to report topline results later this year from its ongoing Phase 3 clinical trial assessing the safety and efficacy of oral avacopan (CCX168) in patients ... Read more

May 9, 2019

Cerebral Small Vessel Disease Can Be Detected Before Diagnosis of MPO-AAV, Study Suggests

News

In patients with MPO-positive ANCA-associated vasculitis, the excess inflammation causes cerebral small vessel disease even before the disease is diagnosed, and the risk for cerebral disease may remain high ... Read more

May 7, 2019

Stopping Immunosuppressants May Be OK for Some ANCA Vasculitis Patients, Study Suggests

News

A large proportion of patients with ANCA-associated vasculitis discontinue treatment while in remission, but they appear to have fewer relapses than those who never stopped treatment, a study has ... Read more

Pin It on Pinterest